Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 50

1.

Myelopoiesis, metabolism and therapy: a crucial crossroads in cancer progression.

Sica A, Guarneri V, Gennari A.

Cell Stress. 2019 Jul 1;3(9):284-294. doi: 10.15698/cst2019.09.197. Review.

2.

Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer.

Pietri E, Massa I, Bravaccini S, Ravaioli S, Tumedei MM, Petracci E, Donati C, Schirone A, Piacentini F, Gianni L, Nicolini M, Campadelli E, Gennari A, Saba A, Campi B, Valmorri L, Andreis D, Fabbri F, Amadori D, Rocca A.

Oncologist. 2019 Jun;24(6):743-e205. doi: 10.1634/theoncologist.2018-0243. Epub 2018 Dec 27.

3.
4.

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.

Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas MP, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O'Reilly S, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribi K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber RD, Coates AS, Di Leo A, Regan MM, Goldhirsch A; SOLE Investigators.

Lancet Oncol. 2018 Jan;19(1):127-138. doi: 10.1016/S1470-2045(17)30715-5. Epub 2017 Nov 17.

PMID:
29158011
5.

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators.

N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5. Erratum in: N Engl J Med. 2017 Aug 17;377(7):702. Erratum in: N Engl J Med. 2018 Oct 18;379(16):1585.

6.

Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer.

Campora S, Campazzi E, Zanardi S, Puntoni M, Piccininno M, Piccardo A, Shoushtari Zadeh Naseri M, Defferrari C, Provinciali N, Petrera M, Marra D, Biscaldi E, Antonucci GC, Ricci D, Clavarezza M, Gennari A, Gozza A, D'Amico M, Mori M, DeCensi A.

Transl Oncol. 2016 Dec;9(6):600-605. doi: 10.1016/j.tranon.2016.08.001. Review.

7.

Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy.

Gennari A, Amadori D, Scarpi E, Farolfi A, Paradiso A, Mangia A, Biglia N, Gianni L, Tienghi A, Rocca A, Maltoni R, Antonucci G, Bruzzi P, Nanni O.

Breast Cancer Res Treat. 2016 Aug;159(1):79-86. doi: 10.1007/s10549-016-3923-8. Epub 2016 Jul 26.

PMID:
27460638
8.

Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials.

Clavarezza M, Puntoni M, Gennari A, Paleari L, Provinciali N, D'Amico M, DeCensi A.

Clin Cancer Res. 2016 Sep 15;22(18):4594-603. doi: 10.1158/1078-0432.CCR-15-1881. Epub 2016 May 2.

9.

Cancer and fertility preservation: international recommendations from an expert meeting.

Lambertini M, Del Mastro L, Pescio MC, Andersen CY, Azim HA Jr, Peccatori FA, Costa M, Revelli A, Salvagno F, Gennari A, Ubaldi FM, La Sala GB, De Stefano C, Wallace WH, Partridge AH, Anserini P.

BMC Med. 2016 Jan 4;14:1. doi: 10.1186/s12916-015-0545-7.

10.

International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013).

Amoroso V, Generali D, Buchholz T, Cristofanilli M, Pedersini R, Curigliano G, Daidone MG, Di Cosimo S, Dowsett M, Fox S, Harris AL, Makris A, Vassalli L, Ravelli A, Cappelletti MR, Hatzis C, Hudis CA, Pedrazzoli P, Sapino A, Semiglazov V, Von Minckwitz G, Simoncini EL, Jacobs MA, Barry P, Kühn T, Darby S, Hermelink K, Symmans F, Gennari A, Schiavon G, Dogliotti L, Berruti A, Bottini A.

J Natl Cancer Inst Monogr. 2015 May;2015(51):90-6. doi: 10.1093/jncimonographs/lgv023.

11.

Breast cancer incidence after hormonal treatments for infertility: systematic review and meta-analysis of population-based studies.

Gennari A, Costa M, Puntoni M, Paleari L, De Censi A, Sormani MP, Provinciali N, Bruzzi P.

Breast Cancer Res Treat. 2015 Apr;150(2):405-13. doi: 10.1007/s10549-015-3328-0. Epub 2015 Mar 6. Review.

PMID:
25744295
12.

An observational study of nasal cavity toxicity in cancer patients treated with bevacizumab.

D'Amico M, Pagano M, Pasa A, Puntoni M, Clavarezza M, Gennari A, Gozza A, Zanardi S, Defferrari C, Provinciali N, Campazzi E, Campora S, Paleari L, Marra D, Petrera M, DeCensi A.

Expert Opin Drug Saf. 2014 Nov;13(11):1437-42. doi: 10.1517/14740338.2014.960388. Epub 2014 Sep 16.

PMID:
25224760
13.

Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey.

Natoli C, Brocco D, Sperduti I, Nuzzo A, Tinari N, De Tursi M, Grassadonia A, Mazzilli L, Iacobelli S, Gamucci T, Vici P; “FOLLOW-UP” Study Group.

PLoS One. 2014 Apr 8;9(4):e94063. doi: 10.1371/journal.pone.0094063. eCollection 2014.

14.

Anthracycline-free therapy for HER2-amplified breast cancer.

Gennari A, Mastro LD.

Lancet Oncol. 2013 Oct;14(11):1037-1038. doi: 10.1016/S1470-2045(13)70410-8. Epub 2013 Sep 3. No abstract available.

PMID:
24007747
15.

Body mass index and prognosis of metastatic breast cancer patients receiving first-line chemotherapy.

Gennari A, Nanni O, Puntoni M, DeCensi A, Scarpi E, Conte P, Antonucci G, Amadori D, Bruzzi P.

Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1862-7. doi: 10.1158/1055-9965.EPI-13-0595. Epub 2013 Aug 14.

16.

Identification and validation of a new set of five genes for prediction of risk in early breast cancer.

Mustacchi G, Sormani MP, Bruzzi P, Gennari A, Zanconati F, Bonifacio D, Monzoni A, Morandi L.

Int J Mol Sci. 2013 May 6;14(5):9686-702. doi: 10.3390/ijms14059686.

17.

Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence.

Rossari JR, Metzger-Filho O, Paesmans M, Saini KS, Gennari A, de Azambuja E, Piccart-Gebhart M.

J Oncol. 2012;2012:417673. Epub 2012 Sep 12.

18.

A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer.

Defferrari C, Campora S, D'Amico M, Piccardo A, Biscaldi E, Rosselli D, Pasa A, Puntoni M, Gozza A, Gennari A, Zanardi S, Lionetto R, Bandelloni M, Decensi A.

J Ovarian Res. 2012 Jun 25;5(1):17. doi: 10.1186/1757-2215-5-17.

19.

Exemestane for breast cancer prevention: a critical shift?

Decensi A, Dunn BK, Puntoni M, Gennari A, Ford LG.

Cancer Discov. 2012 Jan;2(1):25-40. doi: 10.1158/2159-8290.CD-11-0248. Review.

20.

Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.

Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, Gennari A, Trabacca MS, Galimberti V, Veronesi P, Johansson H, Aristarco V, Bassi F, Luini A, Lazzeroni M, Varricchio C, Viale G, Bruzzi P, Decensi A.

J Clin Oncol. 2012 Jul 20;30(21):2593-600. doi: 10.1200/JCO.2011.39.3769. Epub 2012 May 7.

PMID:
22564993

Supplemental Content

Loading ...
Support Center